Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready
Portland Technology Holdings LLC currently manages 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners. The portfolio spans 2 distinct art units, showing some technical variety within the company's biotech filings. This structure suggests that while the portfolio is small, it involves navigating different technical standards within the pharmaceutical sector. This requires a prosecution strategy that accounts for the specific technical standards of each unit.
MELLER, MICHAEL V is the busiest examiner for this portfolio, currently overseeing 2 pending office actions. This means MELLER, MICHAEL V is responsible for half of the company's total pending workload of 4 pending office actions. The remaining pending office actions are split between the other 3 distinct examiners. This distribution across 2 distinct art units requires a prosecution strategy that accounts for the varied interpretations of multiple examiners. Practitioners should prioritize the relationship with MELLER, MICHAEL V while ensuring that the arguments made in the other art unit remain consistent.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| Double-patenting + other | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MELLER, MICHAEL V | 2 | 47.2% | +28.0% |
| MOREAU, NASHARA LOUISE | 1 | 66.7% | -80.0% |
| ALAM, AYAAN A | 1 | 38.8% | +36.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18363793 | COMPOSITIONS AND METHODS COMPRISING HEMP EXTRACT FOR THE TREATMENT OF ANIMALS IN NEED | MELLER, MICHAEL V | 13d |
| 18625711 | HEMP EXTRACT FOR TREATMENT OF PAIN, CANCER AND EPILEPSY IN ANIMALS | MOREAU, NASHARA LOUISE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18363793 | COMPOSITIONS AND METHODS COMPRISING HEMP EXTRACT FOR THE TREATMENT OF ANIMALS IN NEED | MELLER, MICHAEL V | 13d |
| 17661122 | HEMP EXTRACT AND METHODS OF USE THEREOF | MELLER, MICHAEL V | — |
| 17597259 | HEMP EXTRACT FOR TREATMENT OF PAIN, CANCER AND EPILEPSY IN ANIMALS | ALAM, AYAAN A | — |
| Art Unit | Apps |
|---|---|
| 1655 | 3 |
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18625711 | HEMP EXTRACT FOR TREATMENT OF PAIN, CANCER AND EPILEPSY IN ANIMALS | MOREAU, NASHARA LOUISE | 1655 | §101§102§103Other | Non-Final OA | — | Pending | Apr 03, 2024 |
| 18363793 | COMPOSITIONS AND METHODS COMPRISING HEMP EXTRACT FOR THE TREATMENT OF ANIMALS IN NEED | MELLER, MICHAEL V | 1655 | §102§103 | Final Rejection | 13d | Pending | Aug 02, 2023 |
| 17661122 | HEMP EXTRACT AND METHODS OF USE THEREOF | MELLER, MICHAEL V | 1655 | §103DP | Non-Final OA | — | Pending | Apr 28, 2022 |
| 17597259 | HEMP EXTRACT FOR TREATMENT OF PAIN, CANCER AND EPILEPSY IN ANIMALS | ALAM, AYAAN A | 1611 | §103DP | Non-Final OA | — | Pending | Dec 30, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPortland Technology Holdings LLC has 4 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Michael V Meller has the most, with 2 of Portland Technology Holdings LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
